EVALUATION OF IMIDAFENACIN ON URINARY SENSATION AND BRAIN FUNCTION USING REAL-TIME MEASUREMENT OF OXYHEMOGLOBIN CONCENTRATION CHANGES IN FRONTAL MICTURITION AREA OF OAB PATIENTS

Hypothesis / aims of study
To investigate imidafenacin’s effects on urinary sensation and brain function using real-time measurement of oxyhemoglobin concentration changes in frontal micturition area of OAB patients using near-infrared spectroscopy (NIRS).

Study design, materials and methods
62 patients with overactive bladder (OAB) due to neurologic diseases (25 men, 37 women; mean age, 70 years) underwent a systematized lower urinary tract symptom (LUTS) questionnaire and cognitive tests (Mini-Mental State Examination [MMSE], Frontal Assessment Battery [FAB], and Alzheimer’s Disease Assessment Scale cognitive subscale [ADAScog]). 35 of them underwent a urodynamics according to the ICS standards, in 8 of whom we performed NIRS during a urodynamics, before and after administration of 3 months, 0.2 mg/day imidafenacin, a cholinergic agent.

Results
Imidafenacin ameliorated night-time frequency (2.6 to 2.0, p<0.05), urinary urgency (daily to weekly, p<0.05), bladder-related QOL (dissatisfied to mildly dissatisfied, p<0.05) while it did not change cognitive results (MMSE 21.8 to 22.1, FAB10.7 to 11.1, ADAScog 14.8 to 14.4). Imidafenacin increased a bladder volume at the strong desire to void (SDV) (223 ml to 266 ml, p<0.05) whereas frequency of detrusor overactivity did not change significantly (22/35 to 19/35). In 8 patients who underwent NIRS, imidafenacin also increased a bladder volume at the first sensation (FS) (114 ml to 137 ml) and SDV (149 ml to 207 ml) without changing cognitive results. In those patients, average oxyhemoglobin concentration subtract from start to FS increased whereas that from start to SDV did not change. Increase of subtract from start to FS was prominent in Brodmann’s area 8,10 of the upper prefrontal cortex.

Interpretation of results
Previous imaging studies have shown that in OAB patients during bladder storage, frontal cortex was deactivated as compared with control. In the present study, imidafenacin ameliorated bladder sensation, without marked disappearance of detrusor overactivity, without cognitive change. This is presumably brought about by imidafenacin’s suppression on the bladder afferent signals by blocking muscarinic receptors, leading to a reversal of frontal deactivation during bladder storage, which might also contribute to an enlarged bladder volume at FS and SDV. However, since this is a small study, clarification with a larger study is needed.

Concluding message
Imidafenacin ameliorated bladder sensation together with oxyhemoglobin concentration increase in frontal micturition area of OAB patients, without cognitive worsening.
K.T.
70 years old male

Figure 1 K.T. showing an increase in oxyhemoglobin concentration in frontal micturition area before and after administration of 3 months, 0.2 mg/day inidafenacin. FS: first sensation, SDV: strong desire to void

Figure 2 Average oxyhemoglobin concentration subtract from start to the first sensation in 6-divided frontal micturition area before and after administration of 3 months, 0.2 mg/day inidafenacin.

Specify source of funding or grant
Nothing

Is this a clinical trial? No

What were the subjects in the study? HUMAN

Was this study approved by an ethics committee? Yes

Specify Name of Ethics Committee Ethics Committee in Sakura Medical Center, Toho University
<table>
<thead>
<tr>
<th>Question</th>
<th>Answer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Was the Declaration of Helsinki followed?</td>
<td>Yes</td>
</tr>
<tr>
<td>Was informed consent obtained from the patients?</td>
<td>Yes</td>
</tr>
</tbody>
</table>